An Extension of Deep Pathway Analysis: A Pathway Route Analysis Framework Incorporating Multi-dimensional Cancer Genomics Data
暂无分享,去创建一个
[1] D. Morris,et al. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer , 2011, Cancer and Metastasis Reviews.
[2] A. Adjei,et al. Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.
[3] I. Azimi,et al. Calcium influx pathways in breast cancer: opportunities for pharmacological intervention , 2014, British journal of pharmacology.
[4] L. Harris,et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. , 2001, European journal of cancer.
[5] Eli Upfal,et al. Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.
[6] M. Young,et al. Targeting AMPK for cancer prevention and treatment , 2015, Oncotarget.
[7] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[8] M. Kasper,et al. Hedgehog signalling in breast cancer. , 2009, Carcinogenesis.
[9] Donald J Buchsbaum,et al. The Wnt/β-catenin pathway in ovarian cancer: a review. , 2013, Gynecologic oncology.
[10] Hasan H. Otu,et al. Bayesian Pathway Analysis of Cancer Microarray Data , 2014, PloS one.
[11] Chris Sander,et al. Genomic complexity and AKT dependence in serous ovarian cancer. , 2012, Cancer discovery.
[12] A. Morris,et al. Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells Published, JLR Papers in Press, July 1, 2003. DOI 10.1194/jlr.M300188-JLR200 , 2003, Journal of Lipid Research.
[13] L. Harris,et al. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. , 2001, European journal of cancer.
[14] R. Kidd,et al. Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. , 2013, Breast cancer.
[15] Stefan Wiemann,et al. KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor , 2009, Bioinform..
[16] C. Knabbe,et al. TGF‐Beta Signaling in Breast Cancer , 2006, Annals of the New York Academy of Sciences.
[17] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[18] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] Hwa-Yong Lee,et al. Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype , 2015, Scientific Reports.
[20] A. Chariot,et al. NF-κB, stem cells and breast cancer: the links get stronger , 2011, Breast Cancer Research.
[21] A. Leary,et al. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges , 2015, Chinese journal of cancer.
[22] P. Cassoni,et al. Oxytocin Receptor Signaling in Myoepithelial and Cancer Cells , 2005, Journal of Mammary Gland Biology and Neoplasia.
[23] Søren Højsgaard,et al. Graphical Independence Networks with the gRain Package for R , 2012 .
[24] Yue Zhao,et al. Deep pathway analysis incorporating mutation information and gene expression data , 2016, 2016 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).
[25] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[26] Michael L. Gatza,et al. Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.
[27] Yong Lin,et al. Tumor necrosis factor and cancer, buddies or foes? , 2008, Acta Pharmacologica Sinica.
[28] Ronald J. Moore,et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.
[29] David C. Corney,et al. Role of p53 and Rb in ovarian cancer. , 2008, Advances in experimental medicine and biology.
[30] S. Mabuchi,et al. Targeting mTOR signaling pathway in ovarian cancer. , 2011, Current medicinal chemistry.
[31] M. Quinn,et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden , 2014, BMC Cancer.
[32] David Haussler,et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..
[33] Dong-Guk Shin,et al. A route-based pathway analysis framework integrating mutation information and gene expression data. , 2017, Methods.
[34] H. Hondermarck,et al. Neurotrophins and their receptors in breast cancer. , 2012, Cytokine & growth factor reviews.
[35] Kathleen Marchal,et al. Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration , 2015, PloS one.
[36] Nir Friedman,et al. Probabilistic Graphical Models - Principles and Techniques , 2009 .
[37] Gong Yang,et al. Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling , 2016, Cancer medicine.
[38] A. Gerger,et al. Hedgehog Signaling Pathway in Ovarian Cancer , 2013, International journal of molecular sciences.
[39] Pooja Mittal,et al. A novel signaling pathway impact analysis , 2009, Bioinform..
[40] I. Galve-Roperh,et al. Involvement of the cAMP/protein kinase A pathway and of mitogen‐activated protein kinase in the anti‐proliferative effects of anandamide in human breast cancer cells , 1999, FEBS letters.
[41] Yoon-Jae Cho,et al. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. , 2012, Cold Spring Harbor perspectives in medicine.
[42] S. Hilsenbeck,et al. Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.
[43] Hongzhe Li,et al. In Response to Comment on "Network-constrained regularization and variable selection for analysis of genomic data" , 2008, Bioinform..
[44] Joyce Lee,et al. PI3K/Akt/mTOR inhibitors in breast cancer , 2015, Cancer biology & medicine.
[45] Qiang Hu,et al. Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium. , 2016, Carcinogenesis.
[46] David N. Rider,et al. Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer , 2011, Cancer Causes & Control.
[47] O Sukocheva,et al. Role of sphingolipids in oestrogen signalling in breast cancer cells: an update. , 2014, The Journal of endocrinology.
[48] Cengizhan Ozturk,et al. Pathway analysis of high-throughput biological data within a Bayesian network framework , 2011, Bioinform..